CD19 and neoplasm: Next, we compared the proportion of CD4, CD8, CD19, CD68 and Foxp3 positive cells in lymphocytes of patients with high and low expression of ICOSLGTCs, as well as the proportion of CD4, CD8 positive cells and Fopx3+ cells, and divided them into invasive Frontier (Figure 5C) and tumor center (Figure 5D) for analysis.